Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment

BACKGROUND: Bortezomib is a proteasome inhibitor with minimal clinical activity as a monotherapy in solid tumours, but its combination with other targeted therapies is being actively investigated as a way to increase its anticarcinogenic properties. Here, we evaluate the therapeutic potential of co-...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor-Harding, B, Agadjanian, H, Nassanian, H, Kwon, S, Guo, X, Miller, C, Karlan, B Y, Orsulic, S, Walsh, C S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261668/
https://www.ncbi.nlm.nih.gov/pubmed/22166800
http://dx.doi.org/10.1038/bjc.2011.546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261668/
https://www.ncbi.nlm.nih.gov/pubmed/22166800
http://dx.doi.org/10.1038/bjc.2011.546

Ejemplares similares